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Abstract Placental growth factor (PlGF) is a member of the
vascular endothelial growth factor (VEGF) family that binds
speci¢cally to Flt-1. The biological roles of PlGF and Flt-1
have not yet been de¢ned and the signalling mechanisms medi-
ating cellular actions of PlGF remain poorly understood. In
human umbilical vein endothelial cells, VEGF and PlGF induced
expression of both full-length FosB mRNA and an alternatively
spliced variant, vFosB, with similar e⁄cacy and kinetics. In
contrast, PlGF induced c-Fos expression less strongly than
VEGF, and whereas VEGF strongly upregulated tissue factor
mRNA, PlGF had a negligible e¡ect. PlGF induced c-Fos ex-
pression in porcine aortic endothelial cells speci¢cally express-
ing Flt-1, and FosB expression in the monocytic RAW 264.7
cell line expressing endogenous Flt-1. These ¢ndings show for
the ¢rst time that VEGF and PlGF induce mRNA expression of
the transcription factors FosB and c-Fos, and suggest that these
factors may play a role in the biological responses mediated by
PlGF and Flt-1.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Vascular endothelial growth factor (VEGF or VEGF-A) is
essential for endothelial cell di¡erentiation and angiogenesis
during development of the embryonic vasculature and plays a
major role in neovascularisation in a variety of disease states
[1,2]. Two protein tyrosine kinase receptors for VEGF,
VEGFR2/KDR/Flk-1 and VEGFR1/Flt-1, are essential for
embryonic vascular development [3,4], but signal transduction
and biological responses triggered by VEGF in endothelia are
mediated primarily via KDR [5]. The biological function(s) of
Flt-1, which binds VEGF and is a speci¢c receptor for the
VEGF-related factors, placental growth factor (PlGF) and
VEGF-B, have not yet been de¢ned, and the signalling path-
ways mediating the actions of this receptor are not known.
Current thinking favours the view that Flt-1 functions during
embryogenesis primarily as a ‘decoy’ receptor that negatively
regulates KDR-mediated actions of VEGF [1]. The primary
defect in Flt-1 null mice is an overproduction of endothelial
progenitors [5]. Mice lacking only the Flt-1 kinase domain
develop normally [6], indicating that Flt-1 intracellular signal-
ling is not required for embryonic angiogenesis. Flt-1 can also
directly modulate KDR-mediated biological responses [7]. It
remains a matter for debate whether Flt-1 and speci¢c ligands
for this receptor can induce biological functions or signalling
in endothelial cells [1]. However, Flt-1 mediates PlGF-induced
migration and tissue factor expression in monocytes [8], and
FAK tyrosine phosphorylation and chemotaxis in the mono-
cyte/macrophage RAW 264.7 cell line [9]. Furthermore, PlGF
and Flt-1 have been shown to mediate post-developmental
pathophysiological neovascularisation in adult mice [10,11].
The Fos family of transcription factors play critical roles in
cell proliferation and development [12,13], but their regulation
by PlGF and VEGF in endothelial cells is poorly understood.
The results presented in this paper show, for the ¢rst time,
regulation of FosB mRNA by VEGF and PlGF, and indicate
that in contrast to the e¡ects of VEGF on expression of other
endothelial genes, the ability of PlGF to induce FosB was
similar to that displayed by VEGF. Furthermore, PlGF in-
duced a similar response in Flt-1-expressing RAW 264.7 cells.
These ¢ndings provide evidence that PlGF is able to generate
intracellular signals leading to endothelial FosB expression as
e¡ectively as VEGF, and indicate that FosB may play a role
in mediating biological actions of PlGF via Flt-1.
2. Materials and methods
2.1. Cell culture and VEGF treatment
Human umbilical vein endothelial cells (HUVEC) were obtained
from TCS CellWorks Ltd and grown in EBM medium (Clonetics)
supplemented with 10% foetal bovine serum (FBS), 10 ng/ml human
epidermal growth factor, 12 Wg/ml bovine brain extract and 50 Wg/ml
gentamicin sulphate. Wild type (w.t.) and Flt-1-transfected porcine
aortic endothelial (PAE) cells (kind gift of Dr L. Claesson-Welsh,
Department of Genetics and Pathology, Uppsala University, Sweden)
were grown in Ham’s F-12 medium (Invitrogen) supplemented with
10% FBS and either 100 U/ml penicillin and 100 Wg/ml streptomycin
(PAE/w.t.) or 500 Wg/ml G418 sulphate (PAE/Flt-1). Murine RAW
264.7 cells (European Collection of Cell Cultures) were grown in
Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% FBS,
100 U/ml penicillin and 100 Wg/ml streptomycin. Recombinant human
(h) and mouse (m) growth factors (hVEGF165, hPlGF-1, mVEGF164,
mVEGF120 and mPlGF-2) were obtained from RpD Systems and
used at 25 ng/ml (0.6^0.9 nM). For growth factor stimulation experi-
ments, con£uent cultures of HUVEC and PAE cells were rendered
quiescent by incubation in supplement-free, reduced serum (0.3%)
medium overnight. RAW 264.7 cells were used at 70% con£uence.
Prior to addition of growth factors, cells were washed once with
serum and supplement-free medium and then incubated in serum
and supplement-free medium with or without the addition of growth
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factors for 20 min to 24 h. At the end of incubations, cells were
washed twice with ice-cold phosphate-bu¡ered saline and RNA sub-
sequently extracted.
2.2. RNA isolation and semi-quantitative reverse transcription
polymerase chain reaction (RT-PCR)
Total RNA was isolated using the RNeasy mini kit (Qiagen) ac-
cording to the manufacturer’s instructions. During RNA puri¢cation
an on-column DNase digestion was performed using the RNase-free
DNase set (Qiagen) to remove any residual chromosomal DNA. First
strand cDNA was synthesised from 2 Wg of each DNA-free total
RNA sample with Superscript II RNase H3 reverse transcriptase
and oligo(dT)1218 primer (Invitrogen). PCR reactions were per-
formed on a PTC-100 programmable thermal controller (MJ Re-
search) using the Taq PCR master mix kit (Qiagen) and gene-speci¢c
oligonucleotide primers (Table 1) synthesised by MWG Biotech Ltd.
The PCR cycle number required for ampli¢cation to be within the
exponential phase was experimentally determined for each primer
pair. First strand cDNAs were normalised with respect to expression
of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). PCR products were resolved on 1% agarose gels and vi-
sualised by ethidium bromide staining.
2.3. Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was performed on the LightCycler
system (Roche Diagnostics) using ¢rst strand cDNA (generated as
above) in conjunction with the LightCycler-FastStart DNA Master
SYBR Green I kit and gene-speci¢c oligonucleotide primers (Table
1). Primers were designed using the public domain Primer 3 program
(available at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_
www.cgi) to amplify products between 200 and 300 bp in size, with
an optimum of 250 bp. PCR reactions were set up and performed
according to the manufacturer’s instructions, with ampli¢cation spec-
i¢city con¢rmed by melting point analysis. Data were normalised with
respect to expression of GAPDH and scaled relative to expression in
control unstimulated cells.
3. Results
The e¡ects of hVEGF165 and hPlGF-1 on expression of Fos
genes in HUVEC were determined using real-time quantita-
tive RT-PCR at di¡erent time points using gene-speci¢c oli-
gonucleotide primers and GAPDH as a reference gene.
VEGF165 and PlGF-1 both markedly induced expression of
FosB with similar time courses. VEGF165 and PlGF-1 induced
detectable increases in FosB expression after 20 min, maxi-
mum e¡ects of 43T 6-fold and 37T 2-fold above the control
level after 45 min, respectively, and expression thereafter de-
clined to basal levels after 3 h (Fig. 1A). FosB is expressed in
two forms, a full-length form and an alternatively spliced
variant, vFosB, encoding a truncated protein lacking part of
the carboxy-terminal domain [14]. Semi-quantitative RT-PCR
analysis of the FosB mRNAs induced by VEGF and PlGF
showed upregulation of both mRNA species (Fig. 1B). VEGF
and PlGF also both induced expression of c-Fos, but VEGF
consistently produced a stronger induction of c-Fos compared
with PlGF (Fig. 1C). Induction of c-Fos by both factors
reached a maximum after 20 min and declined to the control
level after only 90 min. Neither VEGF nor PlGF signi¢cantly
increased expression of Fos-related antigen-1 (Fra-1), or
members of the Jun family of transcription factors that het-
erodimerise with Fos, including c-Jun, JunB, and JunD (re-
sults not shown). Fra-2 expression was not detected in HU-
VEC (results not shown). Western blotting of whole cell or
nuclear extracts prepared from HUVEC treated with either
PlGF or VEGF did not detect c-Fos or FosB protein (results
not shown).
Table 1
Primers used for semi-quantitative and real-time quantitative RT-PCR
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It was investigated whether PlGF had any e¡ect on other
known VEGF-induced genes. In particular, since PlGF has
previously been reported to increase surface expression of
tissue factor in monocytes [8], it was examined whether
PlGF could induce tissue factor mRNA. As shown in Fig.
1D, VEGF produced a striking induction of tissue factor
mRNA that was rapid, reaching a maximum increase above
the control after 45 min, and thereafter declined slowly to
near the control level after 24 h. In contrast, PlGF caused
no detectable increase in tissue factor mRNA expression
over the same time course. In addition, PlGF also had no
signi¢cant e¡ect on several other genes that were strongly
upregulated by VEGF, including Egr3 and the nuclear recep-
tor Nur77 [15].
The role of Flt-1 in mediating induction of FosB and c-Fos
mRNAs by VEGF and PlGF was further investigated in cells
expressing Flt-1 with no endogenous KDR/Flk-1 expression.
In PAE cells stably transfected with Flt-1 (PAE/Flt-1), PlGF
Fig. 1. E¡ects of VEGF165 and PlGF-1 on FosB and c-Fos mRNA expression in HUVEC. Con£uent cultures of HUVEC were serum-starved
overnight, and treated for the times indicated with 0.6 nM (25 ng/ml) of hVEGF165 (left panels) or 0.9 nM (25 ng/ml) hPlGF-1 (right). Expres-
sion of FosB (A,B), c-Fos (C) and tissue factor (TF, D) mRNA levels were determined by real-time quantitative RT-PCR (A,C,D) and normal-
ised to levels of the housekeeping gene GAPDH or by semi-quantitative RT-PCR (B). The results in A, C and D represent the meansTS.D. of
three experiments. In B, the products of FosB RT-PCR were resolved into species corresponding to full-length (FosB) and truncated (vFosB)
mRNAs. GAPDH mRNA levels are shown as a control reference gene (lower panel). The results shown are representative of four experiments.
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stimulated c-Fos expression, but had no e¡ect in the parental
wild-type PAE cells (Fig. 2). VEGF had a similar e¡ect on
c-Fos expression with maximum fold increases at 20 min of
3.9 T 0.5 and 3.6T 0.1 in PAE/KDR cells and PAE/Flt-1 cells,
respectively (results not shown). The lack of an available se-
quence for the porcine FosB gene prevented analysis of FosB
expression in PAE/Flt-1 cells.
Regulation of Fos genes through a PlGF/Flt-1 pathway was
Fig. 2. Regulation of c-Fos expression in PAE/Flt-1 cells. Con£uent
and quiescent PAE/w.t. (A) and PAE/Flt-1 (B) cells were treated
with 0.9 nM nM (25 ng/ml) hPlGF-1 for the times indicated. Por-
cine c-Fos mRNA levels were determined by real-time quantitative
RT-PCR and normalised to GAPDH mRNA levels. The results
shown represent the mean of three experimentsT S.D.
Fig. 3. KDR and Flt-1 expression in HUVEC and RAW 264.7 cells.
KDR and Flt-1 mRNA levels were determined by semi-quantitative
RT-PCR, using human/mouse gene-speci¢c PCR primers. Corre-
sponding GAPDH mRNA levels are shown. The results shown are
representative of four experiments.
Fig. 4. PlGF induces FosB mRNA expression in RAW 264.7 cells.
RAW 264.7 cells were treated for the times indicated with 0.6 nM
mVEGF164 (A), 0.9 nM mVEGF120 (B), 0.6 nM mPlGF-2 (C), or
0.9 nM hPlGF-1 (D). All growth factors were used at 25 ng/ml.
FosB mRNA levels were determined by real-time quantitative RT-
PCR and normalised to GAPDH mRNA levels. The results shown
represent the meansTS.D. of three experiments.
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next examined in the mouse monocyte/macrophage RAW
264.7 cell line, which has previously been shown to express
Flt-1, but not KDR/Flk-1, and to display Flt1-mediated re-
sponses [9]. Evaluation of VEGF receptor mRNA expression
in RAW 264.7 cells showed that these cells expressed Flt-1,
but lacked detectable KDR expression (Fig. 3). Treatment of
RAW 264.7 cells with the Flt-1 ligands, mVEGF164,
mVEGF120, mPlGF-2, or hPlGF-1, induced FosB mRNA
(Fig. 4). All these Flt-1 ligands also induced c-Fos expression
(results not shown).
4. Discussion
These ¢ndings demonstrate for the ¢rst time that VEGF
and the Flt1-speci¢c ligand PlGF are able to induce mRNA
expression of the transcription factor FosB and indicate that
these factors also upregulate c-Fos expression though with
di¡erent e⁄cacies. The fact that PlGF and VEGF elicited a
similar fold increase in FosB expression with similar kinetics,
in both HUVEC and Flt-1-expressing RAW 264.7 cells,
strongly indicates that Flt-1 is able to mediate induction of
this gene as e¡ectively as KDR. The stronger induction of
c-Fos by VEGF compared with the e¡ect of PlGF suggests
that Flt-1 mediates a weaker c-Fos induction than KDR. The
fact that PlGF was not able to induce signi¢cant expression of
several other immediate early genes strongly upregulated by
VEGF, including tissue factor, suggests that FosB may be one
of a distinct subset of genes commonly regulated by VEGF
and PlGF via Flt-1.
Though the members of the Fos family (c-Fos, FosB, Fra-1
and Fra-2) are among the best studied immediate early genes,
their roles in VEGF signalling and functions are poorly
understood and have been the subject of little investigation.
Fos proteins only heterodimerise with members of the Jun
family to form a large array of AP-1 transcription factor
complexes, which are implicated in a variety of di¡erent cel-
lular and biological processes [12]. The major phenotype of
mice de¢cient in c-Fos is a lack of osteoclasts resulting in
osteopetrosis, whereas ectopic transgenic expression results
in osteoblast transformation leading to osteosarcoma [13].
Mice lacking FosB are viable, but display a profound de¢-
ciency in nurturing of young animals resulting in greatly in-
creased post-natal mortality in their o¡spring [16]. vFosB is a
naturally occurring truncated form of FosB arising from al-
ternative processing of the FosB mRNA, to yield an mRNA
species encoding a protein lacking the transactivation domain
and TBP (TATA binding protein) binding motif [14]. Trans-
genic overexpression of vFosB in mice inhibits adipogenesis,
and independently increases bone formation leading to osteo-
sclerosis [17], while overexpression of vFosB speci¢cally in
thymocytes causes aberrant T cell development [18]. VEGF
and PlGF similarly induced expression of both the full-length
FosB and vFosB transcripts in HUVEC. Since vFosB can act
in a dominant negative fashion to regulate transcription medi-
ated via Fos, FosB and Jun proteins, upregulation of this
form may act to regulate activity of full-length FosB down-
stream of Flt-1.
Despite the critical role of Flt-1 in angiogenesis revealed by
Flt-1 null mice, it has proved extremely di⁄cult to establish
unequivocally that VEGFR1 or speci¢c ligands for this recep-
tor can mediate biological e¡ects or signal transduction in
endothelial cells. Earlier studies largely failed to ¢nd evidence
for PlGF stimulation of endothelial cellular functions such as
migration or proliferation in cells naturally expressing Flt-1,
or in PAE/Flt-1 cells. Flt1 is a weaker tyrosine kinase than
KDR/Flk-1 [19,20], and though Flt-1 has been shown to me-
diate tyrosine phosphorylation of phospholipase CQ and acti-
vation of extracellular signal-regulated kinase [21,22], several
studies have yielded varying and sometimes con£icting results
regarding activation of signalling pathways in Flt-1-expressing
cells, and PlGF has generally been found to be weaker than
VEGF in stimulating signalling pathways [23^26]. The ¢nd-
ings presented here provide one of the ¢rst indications that
PlGF acting via Flt-1 can induce gene expression as e¡ectively
as VEGF, and identify FosB and c-Fos transcription factors
as candidate mediators of Flt-1-mediated cellular functions.
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